Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
dichlorphenamide
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05BC03
|
| gptkbp:CASNumber |
120-97-8
|
| gptkbp:chemicalFormula |
C2H4Cl2N2O4S2
|
| gptkbp:contraindication |
severe renal impairment
severe hepatic impairment |
| https://www.w3.org/2000/01/rdf-schema#label |
Keveyis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Strongbridge Biopharma
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
metabolic acidosis dysgeusia paresthesia cognitive disorder |
| gptkbp:usedFor |
hyperkalemic periodic paralysis
hypokalemic periodic paralysis primary periodic paralysis |
| gptkbp:bfsParent |
gptkb:Taro_Pharmaceutical_Industries
|
| gptkbp:bfsLayer |
7
|